Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Exercise of Share Options

26 Sep 2016 13:58

RNS Number : 8392K
IXICO plc
26 September 2016
 

26 September 2016

 

IXICO plc

("IXICO", or the "Company")

 

Exercise of Share Options

 

 

IXICO (AIM: IXI) announces that Derek Hill, CEO, has exercised 1,900 founder options under the IXICO Technologies Limited Unapproved Share Option Scheme (the "Scheme"). Under the terms of the Scheme the new shares issued and allotted in IXICO Technologies Limited are subject to a put and call arrangement resulting in the Company issuing and allotting 29,773 new ordinary shares of 1 pence each in IXICO plc (the "New Ordinary Shares")

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares is expected to be effective on 30 September 2016 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Following the admission to trading of the New Ordinary Shares, IXICO will have 26,473,191 ordinary shares of 1 pence each in issue. The Company does not hold any shares in treasury. Consequently, 26,473,191 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Inspired under the FCA's Disclosure and Transparency Rules.

 

Enquiries:

 

IXICO plc

Derek Hill, CEO

Susan Lowther, CFO

+44 20 3763 7499

 

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Oliver Jackson

+44 20 7418 8900

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFEFADIRFIR
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.